Albendazole for the treatment of human gnathostomiasis.

Abstract

The efficacy of albendazole was investigated in 112 patients with symptomatic gnathostomiasis; 49 received 400 mg twice daily, 51 received 400 mg once daily, and 12 patients received placebo, all for 21 d. Subsequent follow-up was for 6 months. Cure (no further swelling) was seen in 93.9% and 94.1% of the treatment groups but in none of the placebo group. Additionally, reductions in eosinophil counts and in immunoglobulin G antibody were observed after treatment. Side effects were minimal. Albendazole may be an effective compound for the treatment of gnathostomiasis.

• Authors: P Kraivichian, M Kulkumthorn, P Yingyourd, P Akarabovorn, C C Paireepai
• Journal: Transactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) 1992 Jul-Aug Vol. 86 Issue 4 Pg. 418-21 ISSN: 0035-9203 [Print] England
• PMID: 1440822 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiparasitic Agents
• Albendazole

Topics

• Adolescent
• Adult
• Aged
• Albendazole (administration & dosage, therapeutic use)
• Animals
• Antiparasitic Agents
• Enzyme-Linked Immunosorbent Assay
• Female
• Gnathostoma (isolation & purification)
• Humans
• Male
• Middle Aged
• Nematode Infections (drug therapy, parasitology)
• Recurrence
• Skin (parasitology)
• Treatment Outcome